Literature DB >> 6223576

Tobramycin inactivation by carbenicillin, ticarcillin, and piperacillin.

H Konishi, M Goto, Y Nakamoto, I Yamamoto, H Yamashina.   

Abstract

The in vitro and in vivo inactivation of tobramycin by carbenicillin, ticarcillin, or piperacillin was investigated by the enzyme immunoassay method in clinically employed dosages. After the addition of an 80-mg dose of tobramycin to 4- to 5-g doses of a penicillin in 100 ml of 0.9% saline or distilled water, the degradation profile of tobramycin appeared to follow a biexponential pattern of decay. Remarkable losses (30 to 40%) of tobramycin combined with carbenicillin or ticarcillin were observed within 1 h, as compared with the later decline. The combination of tobramycin with piperacillin was least inactivating. When the admixture of tobramycin with carbenicillin or piperacillin used in the in vitro study was infused to six volunteers over 1 h, the observed maximum concentrations of tobramycin were on the average 66 and 74% for carbenicillin and piperacillin, respectively, of that observed after tobramycin alone was given. In contrast, the value obtained for tobramycin in combination with piperacillin was close to 90% of the control value. The elimination half-lives of tobramycin combined with the penicillins were slightly shorter than those of tobramycin alone, indicating that the interaction occurs even in patients with normal renal function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223576      PMCID: PMC184782          DOI: 10.1128/AAC.23.5.653

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Analysis of the interactions between piperacillin, ticarcillin, or carbenicillin and aminoglycoside antibiotics.

Authors:  P Chanbusarakum; P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

3.  Interactions of carbenicillin and ticarcillin with gentamicin.

Authors:  M Davies; J R Morgan; C Anand
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

4.  Inactivation of gentamicin by penicillins in patients with renal failure.

Authors:  F R Ervin; W E Bullock; C E Nuttall
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

5.  [Studies on beta-lactam antibiotics for medicinal purpose. IV. Stability of 6-[D(-)-alpha-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid (T-1220) in aqueous solution and body fluid (author's transl)].

Authors:  I Saikawa; S Takano; C Yoshida; E Saito; T Yasuda
Journal:  Yakugaku Zasshi       Date:  1977-09       Impact factor: 0.302

6.  Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin.

Authors:  J E McLaughlin; D S Reeves
Journal:  Lancet       Date:  1971-02-06       Impact factor: 79.321

7.  Laboratory and clinical conditions for gentamicin inactivation by carbenicillin.

Authors:  L J Riff; G G Jackson
Journal:  Arch Intern Med       Date:  1972-12

8.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

9.  Distribution and elimination kinetics of intravenously and intramusculary administered tobramycin in man.

Authors:  J C Péchère; B Roy; R Dugal
Journal:  Int J Clin Pharmacol Biopharm       Date:  1976-12

10.  Therapy of neutropenic rats infected with Pseudomonas aeruginosa.

Authors:  R M Lumish; C W Norden
Journal:  J Infect Dis       Date:  1976-05       Impact factor: 5.226

View more
  8 in total

1.  Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.

Authors:  G R Aronoff; R A Brier; R S Sloan; M E Brier
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease.

Authors:  C E Halstenson; C A Hirata; K L Heim-Duthoy; P A Abraham; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 3.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

4.  Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.

Authors:  H Servais; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  In vitro interaction of aminoglycosides with beta-lactam penicillins.

Authors:  S M Wallace; L Y Chan
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

6.  An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients.

Authors:  G W Roberts; R L Nation; A O Jarvinen; A J Martin
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

7.  Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease.

Authors:  C E Halstenson; M O Wong; C S Herman; K L Heim-Duthoy; M A Teal; M B Affrime; J H Kelloway; W F Keane; W M Awni
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

8.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.